LabCorp Announces Change to Board of Directors

  LabCorp Announces Change to Board of Directors

  Adam H. Schechter Named to the Board of Directors Effective April 1, 2013

Business Wire

BURLINGTON, N.C. -- March 11, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE:LH) today
announced that Adam H. Schechter, Executive Vice President and President,
Global Human Health, Merck, has been appointed to its Board of Directors,
effective April 1, 2013.

“We are delighted that Adam, one of the most senior executives at a global
healthcare leader in prescription medicines, vaccines, biologic therapies, and
consumer care, has accepted our invitation to join the LabCorp Board of
Directors,” said David P. King, Chairman and Chief Executive Officer. “His
extensive business and management experience at Merck includes global and
U.S.-focused roles in sales and marketing,as well as businessand product
development. Adam's capabilities will bring a unique and invaluable
perspective to LabCorp as we continue to execute on our five pillar business

Mr. Schechter joined Merck in 1988 as a sales representative and has held a
number of professional, managerial and executive roles in Merck’s global
pharmaceuticals business. He is a member of Merck's executive committee and
pharmaceutical and vaccines operating committee. Prior to becoming President,
Global Human Health, Mr. Schechter served as President, Global Pharmaceutical
Business from 2007 to 2010. Mr. Schechter serves on the board of directors for
the European Federation of Pharmaceutical Industries and Associations. He is a
Board Member for and an Executive Board Member for the National
Alliance for Hispanic Health. Mr. Schechter is also a member of Global 50, and
has been a member of the National Pharmaceutical Committee, the Healthcare
Leadership Council, the Philadelphia CEO Chamber of Commerce Leadership Group,
and on the boards of Merial and the Merck/Schering-Plough Pharmaceuticals
joint ventures.

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its Specialty Testing Group:
The Center for Molecular Biology and Pathology, National Genetics Institute,
ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink
Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc,
Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox,
and Endocrine Sciences. LabCorp conducts clinical trials testing through its
LabCorp Clinical Trials division. LabCorp clients include physicians,
government agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our company, visit our Web site

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.


Laboratory Corporation of America^® Holdings
Investor/Media Contact:
Stephen Anderson, 336-436-5076
Press spacebar to pause and continue. Press esc to stop.